Comparative Pharmacology
Head-to-head clinical analysis: MIRABEGRON versus MYRBETRIQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRABEGRON versus MYRBETRIQ.
MIRABEGRON vs MYRBETRIQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder filling.
Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder filling, increasing bladder capacity.
50 mg orally once daily, with or without food.
25 mg orally once daily, with or without food, may increase to 50 mg once daily after 4-8 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours, allowing once-daily dosing; steady state reached after 7 days.
Clinical Note
moderateMirabegron + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Mirabegron."
Clinical Note
moderateMirabegron + Doxycycline
Terminal elimination half-life is approximately 50 hours (range 32–80 h) in healthy adults, allowing once-daily dosing.
Approximately 55% of the dose is excreted unchanged in urine, with 45% metabolized; fecal excretion accounts for about 22% (mainly as metabolites).
Primarily renal (55% unchanged) and fecal (43%, mainly as metabolites), with <1% biliary.
Category A/B
Category C
Beta-3 Adrenergic Agonist
Beta-3 Adrenergic Agonist
"The metabolism of Doxycycline can be decreased when combined with Mirabegron."